RxDoctor Payments Data

Jill Saranthus

Family · Jasper, GANPI 1346352721

Payments from drug & device makers

$357in general payments, 2019–2025

Across 17 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$63
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$54
  • Novo Nordisk$46
  • AbbVie$43
  • Genentech USA, Inc.$26
  • Abbott$24
  • plus $101 from 6 others

What the payments were for

  • Food & beverage$357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$357 in reported general payments places this provider in the 45th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$57,805
Medicare patients
252
Services billed
3,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$90,713
JardianceEmpagliflozin59$70,908
MounjaroTirzepatide35$53,276
JanuviaSitagliptin Phosphate46$50,671
TrulicityDulaglutide20$24,819
RybelsusSemaglutide22$21,930
EliquisApixaban20$19,864
XareltoRivaroxaban32$17,303
FarxigaDapagliflozin Propanediol11$14,129
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,958
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$12,141
AndrogelTestosterone11$6,990
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,907
MyrbetriqMirabegron14$6,845
Breo ElliptaFluticasone/Vilanterol16$6,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$46$112,64491 claims
Lilly USA, LLCMounjaro, Trulicity$19$78,09555 claims
AbbVieSynthroid$43$2,56931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 6,258 family providers in Georgia.

Other family in Jasper

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →